A must-read guide for patients with contraindications and precautions for using Pazopanib (Victor)

Pazopanib (trade name) Votrient) is an oral multi-target tyrosine kinase inhibitor that mainly blocks tumor angiogenesis and inhibits tumor growth and spread by inhibiting signaling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. It is currently mainly approved for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It is an important targeted drug for long-term maintenance treatment of many patients. Although the efficacy of pazopanib is accurate, there are certain contraindications and medication precautions during the use of pazopanib. Patients must strictly follow medical instructions before and during medication to avoid serious adverse reactions caused by improper use.

1. Medication contraindications

1.Contraindicated in patients with severe liver damage

The metabolism of pazopanib is mainly completed through the liver's CYP3A4 enzyme system. If the patient has severe liver function impairment (such as Child-Pugh C grade), the drug may not be metabolized and cleared normally, and may accumulate excessively in the body, leading to increased toxicity and serious side effects. Therefore, such patients are generally clearly classified as a prohibited group. Patients with mild to moderate liver function abnormalities can adjust the dose as appropriate under the guidance of a doctor, but liver function indicators must be closely monitored.

2.Contraindicated for those allergic to ingredients

If patients are known to be allergic to pazopanib or its excipients, use should be avoided, as this may cause severe allergic reactions, including rash, dyspnea, and even anaphylactic shock.

3.Contraindicated for pregnant and lactating women

Animal experiments have suggested that pazopanib may cause adverse effects on the fetus, including teratogenesis and embryotoxicity, so its use during pregnancy is extremely risky. At the same time, pazopanib may be excreted through breast milk and may cause potential harm to infants, so it is also explicitly prohibited for breastfeeding women.

4. Prohibited for children and teenagers

At present, clinical research mainly focuses on the adult population. The safety and effectiveness of children and adolescents have not been fully confirmed, so its use is not recommended for this population.

2. Precautions when taking medication

1.Time and method of taking medicine

Pazopanib is usually recommended to be taken once daily on an empty stomach. Must be at least1 hours before eating or 2 after mealsTake the medicine every hour to avoid food affecting the absorption of the medicine. In particular, a high-fat diet will significantly increase the blood concentration of the drug and increase the risk of side effects. Therefore, patients must strictly follow the rules of taking the drug on an empty stomach.

2.Liver function monitoring

Before taking medication and during treatment, liver function tests (such as ALT, AST, bilirubin) should be performed regularly, especially in the first 3 months of treatment. Close monitoring is required. If transaminases are found to be significantly elevated, the doctor may need to suspend the medication or reduce the dose until liver function recovers.

3.Blood pressure management

Pazopanib may cause an increase in blood pressure by inhibiting angiogenesis, and some patients may even develop uncontrollable hypertension. It is recommended to control blood pressure before taking the medication and monitor it regularly during treatment. If blood pressure rises significantly, antihypertensive drugs need to be adjusted promptly or treatment suspended.

4.Heart function assessment

Pazopanib may affect cardiac function, leading to QT interval prolongation or cardiac insufficiency. Patients should undergo electrocardiogram and cardiac function tests before taking the drug. Especially patients with underlying heart disease need to be extra cautious and perform dynamic monitoring during treatment if necessary.

5.Avoid taking with certain medications

Pazopanib is mainly metabolized by CYP3A4, so when combined with strong inhibitors of CYP3A4 (such as ketoconazole, clarithromycin) or inducers (such as rifampicin, phenytoin), it may significantly change the blood concentration, leading to reduced efficacy or enhanced toxicity. In addition, long-term combined use with antacids or proton pump inhibitors is not recommended, as drug absorption will be reduced.

6.Bleeding and thrombosis risk

While pazopanib inhibits tumor angiogenesis, it may increase the risk of bleeding or thrombotic events, especially in patients with previous bleeding tendencies or who are receiving anticoagulant therapy. They should be used with caution and strictly monitored.

3. Common adverse reactions and treatment suggestions

1.Gastrointestinal reactions: such as diarrhea, nausea, vomiting, loss of appetite, etc. Mild symptoms can be alleviated through dietary adjustments or symptomatic treatment. In severe cases, the drug needs to be discontinued.

2.Abnormal liver function: manifested as elevated transaminases, jaundice, etc. Liver function must be reviewed regularly, and the dosage must be reduced or discontinued if necessary.

3.Skin and hair changes: including hair whitening, rash, discoloration, etc., are generally not life-threatening, but may affect quality of life.

4. Fatigue and fatigue: relatively common, you need to pay attention to rest and adjust your daily routine.

5.Hypertension: If blood pressure continues to rise, antihypertensive drugs should be adjusted or pazopanib should be suspended.

4. Suggestions on daily medication management for patients

You should avoid drinking grapefruit juice during medication, because it will inhibitCYP3A4, resulting in increased blood drug concentration.

Maintain a regular life and avoid high-salt and high-fat diets to reduce the burden on the liver and cardiovascular system.

If symptoms such as severe diarrhea, severe abdominal pain, obvious jaundice, difficulty breathing or heart palpitations occur, you should stop taking the medicine immediately and seek medical advice.

Patients and their families should establish medication records, regularly review blood routine, liver and kidney function and blood pressure, and conduct electrocardiogram monitoring if necessary.

Pazopanib (Pazopanib) is an effective oral targeted drug that has shown good clinical value in the treatment of advanced renal cancer and soft tissue sarcoma. However, due to its metabolic pathways and mechanism of action, the drug may cause liver function damage, increased blood pressure, cardiotoxicity and other problems. Therefore, patients must check for contraindications before taking the medication, strictly follow the doctor's instructions during the medication, and closely monitor liver function, blood pressure and heart conditions. At the same time, attention should be paid to the interaction between diet and drugs, and avoid adjusting the dosage or stopping the drug at will. Only by taking pazopanib in a reasonable and standardized manner under the guidance of a doctor can the drug's efficacy be maximized and risks reduced.

Reference link:https://www.drugs.com